Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.18
-0.10 (-0.97%)
Oct 6, 2025, 4:00 PM EDT - Market closed
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
$664.23M
Revenue Growth
+55.35%
P/S Ratio
5.16
Revenue / Employee
$2,838,571
Employees
234
Market Cap
3.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TLX News
- 13 days ago - CMS Grants Transitional Pass-Through Status for Gozellix - GlobeNewsWire
- 17 days ago - Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman - GlobeNewsWire
- 25 days ago - Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again – Hagens Berman - GlobeNewsWire
- 27 days ago - Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 27 days ago - Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis - GlobeNewsWire
- 4 weeks ago - Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable - Seeking Alpha
- 5 weeks ago - Telix Gets Second FDA Rejection For Kidney Cancer Drug - Benzinga